Evaluation of Cytotoxicity Effects of Chalcone Epoxide Analogues as a Selective COX-II Inhibitor in the Human Liver Carcinoma Cell Line
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: Study of the mechanisms involved in cancer progression suggests that cyclooxygenase enzymes play an important role in the induction of inflammation, tumor formation, and metastasis of cancer cells. Thus, cyclooxygenase enzymes could be considered for cancer chemotherapy. Among these enzymes, cyclooxygenase 2 (COX-2) is associated with liver carcinogenesis. Various COX-2 inhibitors cause growth inhibition of human hepatocellular carcinoma cells, but many of them act in the COX-2 independent mechanism. Thus, the introduction of selective COX-2 inhibitors is necessary to achieve a clear result. The present study was aimed to determine the growth-inhibitory effects of new analogues of chalcone epoxide as selective COX-2 inhibitors on the human hepatocellular carcinoma (HepG2) cell line. Methods: Estimation of both cell growth and the amount of prostaglandin E2 (PGE2) production were used to study the effect of selective COX-2 inhibitors on the hepatocellular carcinoma cell. Cell growth determination has done by MTT assay in 24 h, 48 h and 72 h, and PGE2 production has estimated by using ELYSA kit in 48 h and 72 h. Results: The results showed growth inhibition of the HepG2 cell line in a concentration and time-dependent manner, as well as a reduction in the formation of PGE2 as a product of COX-2 activity. Among the compounds those analogues with methoxy and hydrogen group showed more inhibitory effect than others. Conclusion: The current in-vitro study indicates that the observed significant growth-inhibitory effect of chalcone-epoxide analogues on the HepG2 cell line may involve COX-dependent mechanisms and the PGE2 pathway parallel to the effect of celecoxib. It can be said that these analogues might be efficient compounds in chemotherapy of COX-2 dependent carcinoma specially preventing and treatment of hepatocellular carcinomas.
Abstract
Objectives: Study of the mechanisms involved in cancer progression suggests that cyclooxygenase enzymes play an important role in the induction of inflammation, tumor formation, and metastasis of cancer cells. Thus, cyclooxygenase enzymes could be considered for cancer chemotherapy. Among these enzymes, cyclooxygenase 2 (COX-2) is associated with liver carcinogenesis. Various COX-2 inhibitors cause growth inhibition of human hepatocellular carcinoma cells, but many of them act in the COX-2 independent mechanism. Thus, the introduction of selective COX-2 inhibitors is necessary to achieve a clear result. The present study was aimed to determine the growth-inhibitory effects of new analogues of chalcone epoxide as selective COX-2 inhibitors on the human hepatocellular carcinoma (HepG2) cell line. Methods: Estimation of both cell growth and the amount of prostaglandin E2 (PGE2) production were used to study the effect of selective COX-2 inhibitors on the hepatocellular carcinoma cell. Cell growth determination has done by MTT assay in 24 h, 48 h and 72 h, and PGE2 production has estimated by using ELYSA kit in 48 h and 72 h. Results: The results showed growth inhibition of the HepG2 cell line in a concentration and time-dependent manner, as well as a reduction in the formation of PGE2 as a product of COX-2 activity. Among the compounds those analogues with methoxy and hydrogen group showed more inhibitory effect than others. Conclusion: The current in-vitro study indicates that the observed significant growth-inhibitory effect of chalcone-epoxide analogues on the HepG2 cell line may involve COX-dependent mechanisms and the PGE2 pathway parallel to the effect of celecoxib. It can be said that these analogues might be efficient compounds in chemotherapy of COX-2 dependent carcinoma specially preventing and treatment of hepatocellular carcinomas.
참고문헌 (43)
- Schiff ER, "Schiff's diseases of the liver", pp.1281~1304 (1999), Lippincott-Raven Publishers
- diagnosis, "Hepatic tumors and cysts. Sleisenger &Fordtran’s gastrointestinal and liver disease: pathology", pp.Saunders, management
- Okuda K, "Changing incidence of hepatocellular carcinoma in Japan", Cancer research, 47(18), pp.4967~4972 (1987)
- Taylor-Robinson SD, "Increase in primary liver cancer in the UK, 1979-94", Lancet, 350(9085), pp.1142~1143 (1997)
- Deuffic S, "Trends in primary liver cancer", Lancet, 351(9097), pp.214~215 (1998)
- El-Serag HB, "Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States", Hepatology, 33(1), pp.62~65 (2001)
- Hu KQ, "Rationale and feasibility of chemoprovention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors", J Lab Clin Med, 139(4), pp.234~243 (2002)
- Williams CS, "Aspirin use and potential mechanisms for colorectal cancer prevention", J Clin Invest, 100(6), pp.1325~1329 (1997)
- Buttar NS, "The"aspirin"of the new millennium : cyclooxygenase-2 inhibitors", Mayo Clin Proc, 75(10), pp.1027~1038 (2000)
- Fosslien E, "Biochemistry of cyclooxygenase(COX)-2inhibitors and molecular pathology of COX-2 in neoplasia", Crit Rev Clin Lab Sci, 37(5), pp.431~502 (2000)
- Pai R, "Prostaglandin E2 transactivates EGF receptor : a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy", Nat Med, 8(3), pp.289~293 (2002)
- Cheng J, "Expression of cyclooxygenase 2 and cytosolic phospholipase A(2)in the liver tissue of patients with chronic hepatitis and liver cirrhosis", Hepatol Res, 23(3), pp.185~195 (2002)
- Weddle DL, "β-adrenergic growth regulation of human cancer cell lines derived from pancreatic ductal carcinomas", Carcinogenesis, 22(3), pp.473~479 (2001)
- Davies G, "Cyclooxygenase-2(COX-2), aromatase and breast cancer : a possible role for COX-2 inhibitors in breast cancer chemoprevention", Ann Oncol, 13(5), pp.669~678 (2002)
- Hosomi Y, "Increased cyclooxygenase 2(COX-2)expression occurs frequently in precursor lesions of human adenocarcinoma of the lung", Lung Cancer, 30(2), pp.73~81 (2000)
- Seno H, "Cyclooxygenase 2-and prostaglandin E2receptor EP2-dependent angiogenesis in ApcΔ716 mouse intestinal polyps", Cancer research, 62(2), pp.506~511 (2002)
- Richter M, "Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors", Carcinogenesis, 22(1), pp.17~25 (2001)
- Wu GS, "Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines", World J Gastroenterol, 9(6), pp.1302~1306 (2003)
- Funk CD, "Prostaglandins and leukotrienes : advances in eicosanoid biology", Science, 294(5548), pp.1871~1875 (2001)
- Rigas B, "Altered eicosanoid levels in human colon cancer", J Lab Clin Med, 122(5), pp.518~523 (1993)
- Harizi H, "The impact of eicosanoids on the crosstalk between innate and adaptive immunity : the key roles of dendritic cells", Tissue Antigens, 65(6), pp.507~514 (2005)
- Karin M, "Nuclear factor-κB in cancer development and progression", Nature, 441(7092), pp.431~436 (2006)
- Grivennikov SI, "Immunity, inflammation, and cancer", Cell, 140(6), pp.883~899 (2010)
- Cheng J, "Ns-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines", Int J Cancer, 99(5), pp.755~761 (2002)
- Cui W, "In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells", Clinical cancer research, 11(22), pp.8213~8221 (2005)
- Heiduschka G, "7β-hydroxycholesterol induces apoptosis and regulates cyclooxygenase 2 in head and neck squamous cell carcinoma", Arch Otolaryngol Head Neck Surg, 135(3), pp.261~267 (2009)
- Park W, "Antitumor enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing Cyclooxygenase-2", J Exp Clin Cancer Res, 27(1), pp.66~ (2008)
- Farooqui M, "COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia", Br J Cancer, 97(11), pp.1523~1531 (2007)
- Futaki N, "Selective inhibition of NS-398 on prostanoid production in inflamed tissue in rat carrageenan-air-pouch inflammation", J Pharm Pharmacol, 45(8), pp.753~755 (1993)
- Gans KR, "Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor", J Pharmacol Exp Ther, 254(1), pp.180~187 (1990)
- Mejza F, "Selective inhibitors of cyclooxygenase-2 (COX-2)", Postepy Hig Med Dosw, 55(2), pp.287~302 (2001)
- Polish. Zarghi A, "Design, synthesis and biological evaluation of 5-oxo-1, 4, 5, 6, 7, 8 hexahydroquinoline derivatives as selective cyclooxygenase-2 inhibitors", Iran J Pharm Res, 13, pp.61~69 (2014)
- Williams CS, "The role of cyclooxygenases in inflammation, cancer, and development", Oncogene, 18(55), pp.7908~7916 (1999)
- Koga H, "Expression of cyclooxygenase-2 in human hepatocellular carcinoma : relevance to tumor dedifferentiation", Hepatology, 29(3), pp.688~696 (1999)
- Hu KQ, "Inhibited proliferation of cyclooxygenase-2 expressing human hepatoma cells by NS-398, a selective COX-2 inhibitor", Int J Oncol, 22(4), pp.757~763 (2003)
- Rahman MA, "Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines", Cancer Res, 60(8), pp.2085~2089 (2000)
- Bae SH, "Expression of cyclooxygenase-2(COX-2)in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398", Clin Cancer Res, 7(5), pp.1410~1418 (2001)
- Yamamoto Y, "Sulindac inhibits activation of the NF-κB pathway", J Biol Chem, 274(38), pp.27307~27314 (1999)
- Herrmann C, "Sulindac sulfide inhibits Ras signaling", Oncogene, 17(14), pp.1769~1776 (1998)
- Waddell WR, "Adenomatous polyposis coli, protein kinases, protein tyrosine phosphatase : the effect of sulindac", J Surg Oncol, 58(4), pp.252~256 (1995)
- Piazza GA, "Apoptosis primarily accounts for the growthinhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxy-genase inhibition, cell cycle arrest, and p53 induction", Cancer Res, 57(12), pp.2452~2459 (1997)
- Mi Kyung Park, "Pattern of Apoptosis by N S398, a Selective COX-2 Inhibitor, in H epatocellular Carcinoma Cell Lines", Cancer Research and Treatment, 37(5), pp.313~317 (2005), 대한암학회
- Cheng AS, "Specific COX-2 inhibitor, NS-398, suppresses cellular proliferation and induces apoptosis in human hepatocellular carcinoma cells", Int J Oncol, 23(1), pp.113~119 (2003)